Takeda enters into $1.04B deal for liver disease drug

Takeda has entered into a $1.04 billion licensing agreement with Arrowhead Pharmaceuticals around its phase 2 therapy ARO-AAT, which was designed to treat alpha-1 antitrypsin-associated liver disease.

The therapy was designed to reduce the production of mutant alpha-1 antitrypsin protein, which progresses the liver disease.

Takeda and Arrowhead will co-develop the therapy. If approved, Takeda will lead commercialization efforts and split potential profits in a 50/50 structure.

Arrowhead will receive an upfront payment of $300 million, with the potential to earn $740 million in regulatory and commercial milestones.

More articles on surgery centers:
The 3 things facilities should do now to prepare for the 2021 CMS Physician Fee Schedule
6 must-know coding updates in 2020
Blue Cross North Carolina, Wake Forest collaborate on new insurance network

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers